54results about How to "Effect be exert" patented technology

The present invention relates to a method and a device for transporting a molecule through a mammalian barrier membrane of at least one layer of cells comprising the steps of: ablating said membrane with an electric current from an array of treatment electrodes; and utilizing a driving force to move said molecule through said perforated membrane.

Compounds, compositions and methods that are useful for the treatment of metabolic disorders, inflammatory diseases and cancer are provided herein. In particular, the invention provides compounds which modulate the expression and / or function of proteins involved in lipid metabolism, inflammation and cell proliferation. The subject compounds are linked biaryl compounds.

The present invention includes compositions and methods for designing, making and using modular recombinant antibodies or fragments thereof with one half of a cohesin-dockerin pair that permits the rapid assembly of multivariant antigen conjugates.

Provided is an IL-15 heterodimeric protein, such as an IL-15 / IL-15Rα heterodimeric protein. The IL-15 heterodimeric protein contains protein (I) and protein (II). Protein (I) is recombinantly produced by combining IL-15 or a variant thereof with a first Fc variant, and protein (II) is a second Fc variant, or recombinantly produced by combining IL-15Rα or a variant thereof with a second Fc variant. The first Fc variant and the second Fc variant are preferably linked via a “Knob-into-Hole” mode. Also provided are methods of using the IL-15 heterodimeric proteins to modulate an immune response. The provided IL-15 heterodimeric proteins have significant anti-tumor activity, better biological activity and prolonged in vivo half-life compared to the IL-15 molecule alone.

In a lens driving device of the present invention, each magnet is provide to face an outer circumferential face of a first coil, and face a second coil at a position at which the second coil is provided. A first spring member and a second spring member are configured by a plurality of six springs separated from each other, each coil wire end of the first coil and the two of the second coils being connected to a different spring, respectively, and when moving a lens support (5) in the optical axis direction, electric current is flowed through the first coil, and when moving the lens support in an X-Y direction that is orthogonal to the optical axis, a predetermined electric current is flowed through a predetermined one of the second coils.

The present invention concerns a method of administering at least one active pharmaceutical agent to a patient in need thereof, which method comprises the intranasal administration of a composition comprising a therapeutically effective amount of this agent, phospholipids, one or more C2-C4 alcohols and water, wherein the concentrations of the phospholipids and the one or more alcohols in the composition are in the ranges of 0.2 to 10% and 12 to 30% by weight, respectively, with the water content of said composition being not less than 30% by weight, the phospholipids forming vesicles in said composition. Further are disclosed pharmaceutical compositions and combinations suitable for intranasal delivery.

A dosing system for a liquid or viscous dosing material, including an actuator system, that has at least one actuating element and a nozzle with an outlet opening. The dosing system is designed so that during a movement in a closure direction the actuating element is initially moved in a first partial movement in such a way that the actuating element is separated from the closure element at a stop location, intended for that purpose, and then comes into contact with the closure element at the stop location and exerts an impulse on the closure element. This also relates to a corresponding dosing method.

Disclosed is a novel anti-obesity agent. Also disclosed is a therapeutic method using the anti-obesity agent. The anti-obesity agent comprises a GABAB receptor agonist or a pharmacologically acceptable salt thereof as an active ingredient.

A set formed of a scleral buckle and an encircling band is provided for use in connection with retinal detachment surgery to enable the implantation of both the scleral buckle and encircling band free of any suture. A self-assembling scleral buckle-encircling band combination is secured in place by surface scleral tunnels operative as belt loops to enable the securing of a scleral buckle and encircling band on the eyeball to exert an intended indentation effect for treatment of retinal detachment.

The present invention provides chitosan-based nanoparticles that can protect nucleic acids and deliver the same into gut mucosal cells. Compositions and methods for the expression of therapeutic nucleic acids in cells of the gut mucosa are provided. Compositions and methods for delivering therapeutic proteins systemically from cells of the gut mucosa are also provided.

A physical quantity sensor includes a base substrate, a movable part located on the base substrate and provided on a principal surface of the base substrate, a movable electrode part provided in the movable part, and a fixed electrode part provided on the principal surface of the base substrate and located to be opposed to a movable electrode finger, and the fixed electrode part is connected to fixed electrode wiring provided at the principal surface side of the base substrate, the movable electrode part is connected to movable electrode wiring provided at the principal surface side of the base substrate, and a shield part is provided between the fixed electrode wiring and the movable electrode wiring.

Methods and composition for cell-based therapy as well as somatostatin receptor-based therapy are described. For example, in certain aspects methods for administering an anti-tumor therapy using a signaling defective somatostatin receptor mutant are described. Furthermore, the invention provides compositions and methods involve a somatostatin constitutively active somatostatin receptor mutant.

The present invention is directed to a method of controlling and directing cells, for example to stimulate an immune response, inhibit an immune response, direct tissue regeneration or prevent tissue damage for therapeutic activity through the use of heterodimerically-tethered bispecific protein complex of formula A-X:Y-B. Component A may present X on the surface of a cell, may bind a protein (including a marker) expressed on the surface of an effector cell, or A-X is expressed on the surface of an effector cell, whilst B is specific to an epitope on target cell or tissue of interest. X:Y is a heterodimeric-tether which is formed by a binding interaction between X and Y, which together with A and B assists and effects the controlling and directing of the selected cells.

A sheet feeding apparatus has a sheet accommodating portion, a sheet stacking portion, a lift mechanism, a driving portion provided, and a damper portion. The lift mechanism can be engaged with and disengaged from the driving portion, and if the engagement between the lift mechanism and the driving portion is released, the lift mechanism lowers the sheet stacking portion, the damper portion is engaged with the lift mechanism, and if the engagement between the lift mechanism and the driving portion is released, the damper portion exerts damper effect on the lift mechanism to reduce a lowering speed of the sheet stacking portion, and wherein the damper portion does not exert the damper effect on the lift mechanism until the sheet stacking portion is lowered by a predetermined amount after the engagement between the lift mechanism and the driving portion is released.

The present invention relates to a solution for preservation, perfusion, and / or reperfusion of an organ, especially the heart, for transplantation. The solution contains peptide inhibitor(s) of protein kinase C ε (PKC ε). Methods for using the inventive solution are also disclosed, including methods for preserving an organ for transplantation, for protecting an ischemic organ from damage, for attenuating organ dysfunction after ischemia, for maintaining nitric oxide release and / or inhibiting superoxide release in an ischemic organ, and for protecting an organ from damage when isolated from the circulatory system.

A temperature and / or wear sensor for brake or clutch devices is designed as a thermocouple in which the conductors (20, 22) that are electrically insulated from each other are arranged inside a friction lining (14) and can be connected to each other so as to be electrically conductive by means of a rotatably mounted brake element (12), clutch element or the like, with which the friction lining can be engaged in order to brake or to depress the clutch (FIG. 1). The conductors can be coupled to an electric oscillating circuit.

The present invention relates to the field of cellular and molecular therapy with modified (genetically or growth factor engineered) and unmodified stem cells (SCs). More particularly, the invention relates to a method of systemic treatment of central nervous system (CNS) and other tumors in both intracranial / intraspinal and extracranial / extraspinal sites, using neural stem cells (NSCs), a prototype for solid organ, non-hematopoietic stem cells.

Immunoadhesins active against toxins and pathogens are described, with specific examples directed to immunoadhesins for thwarting pathogens such as anthrax and the common cold. The immunoadhesin-receptor ligand principle can be employed to counter virtually any pathogen, toxicant or toxin, including, e.g., natural and synthetic metabolic poisons.

The invention provides a deodorizing article which can be used semi-permanently and maintains sufficient mechanical strength under usual conditions of use and a method for producing the deodorizing article. The deodorizing article of the invention is produced by dispersing in a medium a clay mineral having meso-pores, gypsum series, a mineral having a pore size greater than that of the gypsum series, and a white inorganic filler, and molding the formed dispersion.

The invention generally relates to substituted 2,3-dihydrobenzofuranyl compounds, and more particularly to a compound represented by Structural Formula (I), or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula (I), or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.

Provided is a heat treatment container having a small size and capable of efficiently performing a heat treatment on a SiC substrate. A heat treatment container is a container for a heat treatment on a SiC substrate 40 under Si vapor pressure. The SiC substrate 40 is made of, at least in a surface thereof, single crystal SiC. The heat treatment container includes a container part 30 and a substrate holder 50. The container part 30 includes an internal space 33 in which Si vapor pressure is caused. The internal space 33 is partially open. The substrate holder 50 is able to support the SiC substrate 40. When the substrate holder 50 supports the SiC substrate 40, an open portion of the container part 30 is covered so that the internal space 33 is hermetically sealed.

A device for securing and holding a plant creeping along a support wire (11), comprising a fastener (12) configured as a skewed-surface, open ring composed of an annular web (21), which delimits an internal volume (13) for receiving the plant through an access opening (16), and a pair of hooks (14, 15), which are bent back outwardly at the ends of said web to form semi-open retaining eyes (17) that are offset in the heightwise direction and make it possible to exert a wedging effect on the support wire due to oblique deformation relative to the vertical direction. The fastener (12) is hingeless and is made in one piece from biodegradable material.

Methods useful for preventing, limiting, or treating ischemia reperfusion injury in a mammal are disclosed. More particularly, this invention relates to administering A2b adenosine receptor antagonists to prevent, limit or treat ischemia reperfusion injury.

Cancer is treated by administration of a hypoxia activated prodrug in combination with an mTOR inhibitor.

Bispecific tetravalent antibodies against IL-17 and TNFa, useful in therapy, e.g. the treatment of rheumatoid arthritis and other autoimmune diseases and / or to reduce pathological inflammatory conditions.

A switch unit has an operation key, a cover member having an opening corresponding to the operation key, and a light emitting device disposed on a rear surface side of the cover member that makes the periphery of the operation key luminous by irradiation with light from a light emitting portion disposed on the periphery of the operation key. A top surface side of the operation key is inserted from the rear surface side of the cover member into the opening. An opposing-mirror portion is disposed on the cover member on at least a peripheral part of the operation key. The opposing-mirror portion has a half-mirror portion and a mirror portion spaced apart from the half-mirror portion with a space therebetween. The half-mirror portion is disposed above the mirror portion. The light emitting portion of the light emitting device faces the space between the half-mirror portion and the mirror portion.

A resonator element includes: a base part; and a resonating arm part that extends from the base part in a first direction and performs flexing vibration, wherein the resonating arm part has one principal surface and the other principal surface opposed to the one principal surface, a first groove part provided along the first direction of the resonating arm part on the one principal surface, a second groove part provided in juxtaposition with the first groove part in a second direction orthogonal to the first direction in a plan view on the other principal surface, a third groove part provided in juxtaposition with the first groove part in the first direction in the plan view and provided nearer the base part side than the first groove on the other principal surface, and a fourth groove part provided in juxtaposition with the second groove part in the first direction in the plan view and provided nearer the base part side than the second groove on the one principal surface, and wherein a sum of a depth of the first groove part and a depth of the second groove part and a sum of a depth of the third groove part and a depth of the fourth groove part are larger than a distance between the one principal surface and the other principal surface.

A filament winding device (100) comprising a liner support device (42) supporting a liner (1), and a hoop winding device (43) that winds a fiber bundle (F) on to the outer peripheral surface (1S) of the liner (1) by rotating centered around the liner (1). The filament winding device (100) is characterized by being capable of simultaneously transporting the liner (1) and the hoop winding device (43), by having the liner support device (42) and the hoop winding device (43) arranged upon a trolley (40A), and moving the trolley (40A).

The present invention encompasses novel splice variant forms of the mu-opioid receptor-1 (MOR-1) and the polynucleotide sequences encoding the MOR-1 splice variants. The invention further encompasses methods of screening for compositions regulating the MOR-1 splice variant activities and the development of therapeutic modalities directed to regulating activity. Regulation of the MOR-1 splice variant activities may impact the physiologic process of analgesia.